{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Theriva Biologics, Inc.
Is Theriva Biologics, Inc. technically bullish or bearish?
As of June 5, 2025, the trend is mildly bearish due to daily moving averages indicating bearish momentum, despite a mildly bullish weekly MACD and a bullish monthly RSI, resulting in mixed signals and underperformance against the S&P 500.
Who are in the management team of Theriva Biologics, Inc.?
As of March 2022, the management team of Theriva Biologics, Inc. includes Mr. Jeffrey Kraws (Non-Executive Independent Chairman), Mr. Steven Shallcross (CEO, CFO, Director), Dr. John Monahan (Director), and Mr. Jeffrey Wolf (Independent Director).
What does Theriva Biologics, Inc. do?
Theriva Biologics, Inc. is a clinical-stage company focused on developing therapeutics for gastrointestinal diseases, classified as a micro-cap with a market cap of $3.82 million. As of March 2025, it reported a net profit loss of $4 million and has no dividend yield.
How big is Theriva Biologics, Inc.?
As of Jun 18, Theriva Biologics, Inc. has a market capitalization of 3.82 million and reported net sales of 0.00 million with a net profit of -24.82 million over the latest four quarters. Shareholder's funds are at 19.07 million, and total assets are 39.74 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
